Home » Stocks » Glaukos Corporation

Glaukos Corporation (GKOS)

Stock Price: $41.75 USD -1.70 (-3.91%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.85B
Revenue (ttm) 211.25M
Net Income (ttm) -37.29M
Shares Out 44.18M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $41.75
Previous Close $43.45
Change ($) -1.70
Change (%) -3.91%
Day's Open 43.19
Day's Range 41.41 - 43.68
Day's Volume 595,821
52-Week Range 23.31 - 76.06

More Stats

Market Cap 1.85B
Enterprise Value 1.75B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.18M
Float 43.17M
EPS (basic) -0.79
EPS (diluted) -1.72
FCF / Share -0.42
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.81M
Short Ratio 10.72
Short % of Float 21.64%
Beta 1.77
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.74
PB Ratio 3.00
Revenue 211.25M
Operating Income -100.96M
Net Income -37.29M
Free Cash Flow -18.53M
Net Cash 100.12M
Net Cash / Share 2.26
Gross Margin 95.81%
Operating Margin -47.79%
Profit Margin -15.60%
FCF Margin -8.77%
ROA -7.21%
ROE -16.67%
ROIC -32.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 4
Overweight 0
Hold 4
Underweight 1
Sell 2

Analyst Consensus: Overweight

Price Target

$48.33*
(15.76% upside)
Low
43.0
Current: $41.75
High
60.0
Target: 48.33
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue23718115911471.7045.5920.95
Revenue Growth30.73%13.83%39.21%59.55%57.28%117.64%-
Gross Profit19815613898.2258.7134.1718.41
Operating Income-50.29-13.00-2.284.24-10.30-13.17-14.20
Net Income15.42-12.95-0.094.52-37.24-12.13-12.64
Shares Outstanding37.3635.3234.3832.9317.472.292.04
Earnings Per Share0.37-0.37-0.12-2.13-5.29-6.21
Operating Cash Flow-0.3718.8626.0912.31-2.19-7.11-13.31
Capital Expenditures-4.72-10.32-6.31-6.28-0.88-0.87-0.85
Free Cash Flow-5.098.5519.786.03-3.07-7.98-14.16
Cash & Equivalents18314911995.8491.202.366.79
Total Debt72.63---9.7019.3517.50
Net Cash / Debt11114911995.8481.51-16.99-10.71
Assets81820716613411726.0230.88
Liabilities14533.1127.6317.1021.4729.5523.71
Book Value67317413811795.19-151-141
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Glaukos Corporation
Country United States
Employees 600
CEO Thomas William Burns

Stock Information

Ticker Symbol GKOS
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NYSE: GKOS
IPO Date June 25, 2015

Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.